My research interests focus on medicinal chemistry and the development of new therapeutic strategies, with particular attention to the interaction between small molecules and biological targets involved in disease. My work has included the design and synthesis of enzyme and protein inhibitors, the study of RNA-binding proteins, and, more recently, targeted degradation approaches.
My current research focuses on targeted degradation strategies for rare neurodegenerative disorders, especially the development of PROTACs and RIBOTACs for prion disease. I am also interested in small molecules able to modulate RNA targets, including pre-miR-21, as a way to explore new therapeutic modalities.
